Genome Editing Market is encountering new opportunities & technological advancements by Key Market Players (CRISPR Therapeutics, Editas Medicine, Egenesis Inc., GenScript) | Forecast to 2030

Genome Editing Market Scope:
Market size value in 2023 - USD 6.4 Billion
Market size value in 2030 - USD 24.0 Billion
CAGR (2023-2030) - 18.0%
Forecast Period - 2023-2030
Segments Covered - Technology, Method, Application, Clinical Applications, End-use & Region.
Geographies Covered - North America, Europe, Asia Pacific, and Row
Sample of Companies Covered - Intellia Therapeutics, Inc., Lonza, Merck KGaA, New England Biolabs, OriGene Technologies, Inc., Precision Biosciences, Sangamo, Takara Bio USA.

Download Sample Pages-https://www.marketdigits.com/request/sample/3705

Browse in-depth TOC on "Genome Editing Market"
178-Tables
95-Figures
332-Pages

North America dominates the market for Genome Editing.
In 2022, North America emerged as the dominant force in the global market, boasting a significant market share, propelled by substantial investments in the research and development of gene editing technologies. The region is poised to sustain its leadership position over the forecasted period, thanks to the active participation of numerous biotechnology and pharmaceutical companies dedicated to advancing genome editing technologies. The United States, in particular, claimed the largest market share for genome editing technology in North America, driven by augmented government funding and support for scientific research and development. Major industry players like Editas Pharmaceuticals, Thermo Fisher Scientific, and CRISPR Therapeutics are expected to contribute to the continued growth of the market in this region, complemented by a rising tide of investment in genomic research.
On the other hand, the Asia Pacific region is poised to experience substantial growth, with China emerging as the primary market for genome editing technology. This surge is attributed to government initiatives that actively promote the advancement of genomic research. The Chinese market, in particular, is set for expansion due to the government's heightened emphasis on precision medicine and the presence of key players like BGI and Hebei Senlang Biotechnology. The region's overall genome editing market is primed for growth, driven by increased investments in research and development, a rising incidence of genetic diseases, and government programs supporting genomic research. These factors collectively indicate significant growth potential for the global genome editing market in the upcoming years.

Ask for Discount- https://www.marketdigits.com/request/discount/3705

Top Key Players Covered in the Report-
AstraZeneca, Caribou Biosciences, Inc., Cellectis S.A., Cibus, Recombinetics, Inc., CRISPR Therapeutics, Editas Medicine, Egenesis Inc., GenScript, Horizon Discovery Group plc, Integrated DNA Technologies, Inc., Intellia Therapeutics, Inc., Lonza, Merck KGaA, New England Biolabs, OriGene Technologies, Inc., Precision Biosciences, Sangamo, Takara Bio USA, Thermo Fisher Scientific, Inc. and Others.

For More Information - Inquire Now!
https://www.marketdigits.com/request/enquiry-before-buying/3705

Recent Developments-
In October 2023, Intellia Therapeutics announced positive results from a Phase I/II clinical trial of its CRISPR-Cas9 gene editing therapy for sickle cell disease. The therapy was found to be safe and well-tolerated, and it led to significant increases in hemoglobin levels and reductions in the number of sickle cell crises.

https://industrytoday.co.uk/market-research-industry-today/emerging-trends-and-innovations-for-the-genome-editing-market-projected-to-reach-usd-240-billion-by-2030

MarketDigits
Email: sales@marketdigits.com

MarketDigits is one of the leading business research and consulting companies that helps clients to tap new and emerging opportunities and revenue areas, thereby assisting them in operational and strategic decision-making. We at MarketDigits believe that a market is a small place and an interface between the supplier and the consumer, thus our focus remains mainly on business research that includes the entire value chain and not only the markets.

This release was published on openPR.